TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: hip joint function at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip joint function at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular condition of the femoral head epiphysis before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: vascular condition of the femoral head epiphysis after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in amino acids concentrations in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Value of creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Behavioral Health Measure-20 (BHM-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Without Respiratory Reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Patients Who Die
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Patients Who Develop Respiratory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Patients Who Require ICU Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of enhanced neuro-activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients receiving thrombolytics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients without local failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Over Time in Fatigue Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Initial clinical success of mitomycin C injection therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall clinical success of mitomycin C injection therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measurement of anesthetized mucous membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on tongue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of key inflammatory mediators and proteases in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Responder status at year one
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper gastrointestinal symptom absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite of Recurrent VTE or VTE Death at 36 Months
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Recurrent VTE or VTE Death at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: Irritable Bowel Syndrome Symptom Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the Number of Tumor-infiltrating CD8+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain during biopsy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMPs and NGAL plasma and tissue levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in probing pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of intact fibroblast growth factor 23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of adverse events following infusion of NKT cells
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in physical abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in pain on the Numerical Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional disability on the Oswestry Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Major Gastric Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Leak
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cartilage thickness in the patello-femoral compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time required for endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Corneal perforation closure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of skeletal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CMAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (ORR) in solid tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: posterior ridge resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recidivism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: shunt fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Whole-body insulin sensitivity (M value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anamnestic Response to Anti-hepatitis A Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anamnestic Response to Anti-hepatitis B Surface Antigen Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Acne Severity at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of IFIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of IFIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference Between Peak Inhibin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete control of pain flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair regrowth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the diagnosis rate of first needle aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ≥50% PSA decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to radiographic disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression Free Survival (PFS) at Month 24
Endpoint domain: Mortality/survival
Primary endpoint: Alive After 1 Year Post Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Alive After 2 Years Post Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants requiring surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from detectable to suppressed HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the Coma Recovery Scale-Revised scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serial organ failure assessment (SOFA) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of circulating exosomal lncRNA-GC1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Autonomous Motivation to Prevent T2DM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Specific VOC detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of total doses delivered on schedule
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: effect on polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical characteristics and outcome of hereditary cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Subjects with Improvement in Neurological Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Waist-circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Activity Score-28 (DAS-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-t (the Area Under the Plasma Concentration-time Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Blood Phenylalanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean age of the first acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to temperature recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiver operating characteristic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Fibrinogen polymerisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with treatment-related adverse events (grade 2 or above)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pressure-Volume Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of Participation Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Perceived Limitation Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction With Participation Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Anxiety Inventory Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relieving of hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enhancement of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Burnout Measure Short version (BMS-10) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brain activity PET Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of hypersensitivity/anaphylactic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cause of death and in-hospital mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in pulmonary microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of MGN1601
Endpoint domain: Adverse events/effects
Primary endpoint: total ischemic burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: silent ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: experience of delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: % PrEP uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % eligible PrEP uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients With a Decrease in Median Tumor SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disc-condyle relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myeloperoxidase enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Eyes With Macular Hole Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-infinity]) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-t]) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary plaque thickness or area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of dermical irritability and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Scores of Validated questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADL-related dexterity Questionnaire 24 (DextQ-24)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Breast Cancer Risk Management Recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended phase II dose (RP2D) of pantoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood steroid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: urinary steroid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Access related complication
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pharmacokinetic parameters of TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in short term memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in focus
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insulin Stimulated Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nasopharyngeal carriage of vaccine-type pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Glycated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with HIV-1-RNA ≤ 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic testing uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Meaningful cancer treatment changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with pre-genetic test education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of overall CSBM Responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post traumatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time in SpO2 target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ReShape Dual Balloon Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Renal clearance (CLr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safe time for apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoflip parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tracer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of days spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of hours spent in the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of procedures performed in the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in procedures performed during hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AUC0-inf of IBI301 and rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of glottic opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of TR1801-ADC
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Steps Taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in laboratory induced falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in real life falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide Attempt Self-Injury Interview (SASII)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With HIV Ribonucleic Acid (RNA) <50 Copies/mL at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Adverse Events at 48 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Due to an Adverse Event at 48 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Irritable Bowel Syndrome assessed by Symptom Severity Score (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MRI visibility of the mesh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible size of the mesh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lumbar spine range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in plasma choline and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in measure of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Established Therapeutic Blood Lipid Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Defection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food intake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of posaconazole post dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on movement at 12 hrs after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Developing Surgical Site Infection
Endpoint domain: Adverse events/effects